That the editors in Frontiers in Pharmacology recently were scheduled to publish an important and perhaps considered by some interests a controversial study authored by the research team at the Front Line COVID-19 Critical Care Alliance (FLCCC). Led by physicians Drs. Pierre Kory and Paul E. Marik, the group of committed physicians/researchers work on the front lines caring for patients as critical care physicians while advocating tirelessly for an open and honest scientific discussion about the results of numerous studies involving the generic drug ivermectin and its possible use to address COVID-19. Their meta-analysis of ivermectin studies was subjected to a particularly rigorous and protracted review process over at Frontiers in Pharmacology and was even scheduled to be published with an abstract online, but somehow, some way, an unnamed expert got involved last minute after the reviews were done and the manuscript was ready for prime time. The publisher cancelled. But just recently, another prominent medical journal, the American Journal of Therapeutics, accepted the manuscript. The world will soon review the numerous studies evidencing positive results, despite rampant censorship.
The FLCCC has spent several months now intensely studying ivermectin research around the world. After this period of intensive research, a comprehensive manuscript was authored and the group concluded that in addition to the evidence associated with the drug in numerous studies, reductions in COVID-19 incidences in regions where ivermectin is widely in use suggests that the generic drug may serve a complementary purpose in an overall response to the pandemic. The physician/researchers do acknowledge that only about half of the clinical trials reviewed were published in peer-reviewed publications.
This is a serious group—not only were they invited to present to the Senate late last year but they also presented directly to the National Institutes of Health COVID-19 Guidelines Panel along side Dr. Andrew Hill affiliated with University of Liverpool. The FLCCC also collaborates with another ivermectin researcher, Dr. Tess Lawrie, who recently presented on the TrialSite Podcast show.
The FLCCC makes the case that health agencies at the national and international level should immediately dedicate resources to not only commence validating the existing ivermectin studies (not just cherry pick studies with neutral results) but also confirm other emerging epidemiological data indicating widespread benefit of ivermectin as part of a treatment regimen. This approach in poor, developing nations may be of particular importance.
Call to Action: Keep an eye out for the FLCCC meta analysis titled “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19.”